Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis

The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis

(2013) Shira Dinner et al.   BRITISH JOURNAL OF HAEMATOLOGY

What do I need to know about immunoglobulin light chain (AL) amyloidosis?

(2012) Angela Dispenzieri et al.   BLOOD REVIEWS

Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis

(2012) Stefan Cordes et al.   CANCER

Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

(2012) Shaji Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

(2011) B. Paiva et al.   BLOOD

Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature

(2010) Sergio Siragusa et al.   ANNALS OF HEMATOLOGY

Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma

(2010) Sumit Madan et al.   MAYO CLINIC PROCEEDINGS

Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score

(2010) Shaji K. Kumar et al.   MAYO CLINIC PROCEEDINGS

Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor

(2008) J. Vela-Ojeda et al.   ANNALS OF HEMATOLOGY